Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital Markets downgrades Conduit, slashes price target

(Sharecast News) - RBC Capital Markets downgraded Conduit Holdings on Friday to 'sector perform' from 'outperform' and cut the price target to 425p from 575p. It said the weaker return on equity outturn for FY24 and outlook for FY25 relative to peers impairs Conduit's proposition as a well-timed new business launch in a hard reinsurance market.

RBC said Conduit has outgrown its initial IPO plans by 30% in 2024 with a greater skew towards Property risks.

"This growth seems to have led to excessive natural catastrophe exposure based on the 2024 performance and 2025 outlook, with returns on equity short of its mid-teens target despite peak pricing conditions and high investment returns," it said.

"Earnings volatility is higher than we appreciated and we believe this adds to the start-up discount attached to the shares."

RBC said that taken together, it thinks the risk-reward screens less attractive now.

"Our current valuation is 0.8x 2025E NAV, against its current level of 0.7x," it said. "On balance, a well covered circa 7% dividend yield is a positive."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.